Clinical Trial Update: Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock [Phase 4]

View source ↗

Summary

An ongoing Phase 4 clinical trial evaluating angiotensin-II as a second vasopressor for septic shock, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock
• Systemic Inflammatory Response Syndrome

Drugs mentioned

• Giapreza (Angiotensin II)

Snippet

Sponsor: Kingman Regional Medical Center | Conditions: Septic Shock, Shock | Phase 4 | Status: RECRUITING